Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antipsychotic Agents | 20 | 2024 | 48 | 9.120 |
Why?
|
| Child | 29 | 2024 | 627 | 3.770 |
Why?
|
| Medicaid | 14 | 2023 | 29 | 3.630 |
Why?
|
| Retrospective Studies | 51 | 2024 | 341 | 3.340 |
Why?
|
| Adolescent | 29 | 2024 | 758 | 3.080 |
Why?
|
| United States | 49 | 2024 | 495 | 2.980 |
Why?
|
| Humans | 86 | 2024 | 4936 | 2.960 |
Why?
|
| Analgesics, Opioid | 8 | 2024 | 73 | 2.810 |
Why?
|
| Psychotropic Drugs | 5 | 2019 | 13 | 2.370 |
Why?
|
| Bipolar Disorder | 5 | 2019 | 10 | 2.340 |
Why?
|
| Analgesics, Non-Narcotic | 3 | 2024 | 6 | 2.230 |
Why?
|
| Female | 57 | 2024 | 2523 | 2.140 |
Why?
|
| Male | 53 | 2024 | 2491 | 2.060 |
Why?
|
| Weight Gain | 6 | 2024 | 27 | 2.040 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 5 | 2021 | 25 | 2.030 |
Why?
|
| Health Services Accessibility | 4 | 2023 | 26 | 1.910 |
Why?
|
| Depressive Disorder, Major | 3 | 2021 | 17 | 1.830 |
Why?
|
| Depression | 13 | 2020 | 125 | 1.610 |
Why?
|
| Body Mass Index | 7 | 2024 | 98 | 1.600 |
Why?
|
| Metformin | 2 | 2023 | 9 | 1.600 |
Why?
|
| Hypertension | 7 | 2022 | 58 | 1.490 |
Why?
|
| Dementia | 12 | 2021 | 50 | 1.460 |
Why?
|
| Aged | 45 | 2024 | 703 | 1.440 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2022 | 3 | 1.410 |
Why?
|
| Asthma | 2 | 2022 | 8 | 1.410 |
Why?
|
| Nursing Homes | 13 | 2019 | 31 | 1.380 |
Why?
|
| Antidepressive Agents | 4 | 2019 | 14 | 1.370 |
Why?
|
| Medicare | 18 | 2024 | 78 | 1.330 |
Why?
|
| Medication Adherence | 10 | 2024 | 69 | 1.320 |
Why?
|
| Healthcare Disparities | 3 | 2019 | 17 | 1.310 |
Why?
|
| Mental Disorders | 3 | 2023 | 48 | 1.260 |
Why?
|
| Polypharmacy | 3 | 2019 | 8 | 1.170 |
Why?
|
| Psychotic Disorders | 2 | 2021 | 4 | 1.080 |
Why?
|
| Diabetes Mellitus | 3 | 2023 | 32 | 1.020 |
Why?
|
| Drug Prescriptions | 4 | 2023 | 25 | 1.010 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2023 | 47 | 0.990 |
Why?
|
| Prescriptions | 2 | 2024 | 19 | 0.940 |
Why?
|
| Aged, 80 and over | 23 | 2024 | 262 | 0.840 |
Why?
|
| Qualitative Research | 1 | 2024 | 38 | 0.840 |
Why?
|
| Acute Pain | 1 | 2023 | 4 | 0.810 |
Why?
|
| Texas | 8 | 2022 | 190 | 0.810 |
Why?
|
| Pneumonia | 4 | 2020 | 20 | 0.800 |
Why?
|
| Hyperglycemia | 1 | 2023 | 10 | 0.780 |
Why?
|
| Managed Care Programs | 3 | 2022 | 7 | 0.770 |
Why?
|
| Hypertriglyceridemia | 1 | 2022 | 3 | 0.740 |
Why?
|
| Insulin Resistance | 1 | 2022 | 6 | 0.740 |
Why?
|
| Metabolic Syndrome | 1 | 2022 | 9 | 0.730 |
Why?
|
| Cholinergic Antagonists | 6 | 2019 | 20 | 0.730 |
Why?
|
| Child Psychiatry | 2 | 2024 | 6 | 0.730 |
Why?
|
| Psychiatry | 1 | 2021 | 2 | 0.690 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 4 | 0.690 |
Why?
|
| Emergency Service, Hospital | 4 | 2024 | 12 | 0.680 |
Why?
|
| Cohort Studies | 17 | 2022 | 115 | 0.670 |
Why?
|
| Urinary Bladder, Overactive | 4 | 2021 | 13 | 0.660 |
Why?
|
| Risk Factors | 8 | 2024 | 159 | 0.650 |
Why?
|
| Child, Preschool | 4 | 2024 | 180 | 0.640 |
Why?
|
| Obesity | 4 | 2023 | 115 | 0.630 |
Why?
|
| Central Nervous System Stimulants | 2 | 2017 | 8 | 0.620 |
Why?
|
| Blood Glucose | 3 | 2023 | 29 | 0.600 |
Why?
|
| Quality of Health Care | 1 | 2019 | 5 | 0.590 |
Why?
|
| Geography | 1 | 2019 | 6 | 0.590 |
Why?
|
| Hospitalization | 6 | 2024 | 38 | 0.590 |
Why?
|
| Homes for the Aged | 5 | 2017 | 11 | 0.580 |
Why?
|
| Physicians | 1 | 2019 | 17 | 0.570 |
Why?
|
| Minority Groups | 1 | 2019 | 35 | 0.570 |
Why?
|
| Antihypertensive Agents | 4 | 2020 | 17 | 0.560 |
Why?
|
| Mental Health Services | 1 | 2018 | 13 | 0.550 |
Why?
|
| Proportional Hazards Models | 11 | 2020 | 28 | 0.540 |
Why?
|
| Medicare Part C | 7 | 2024 | 32 | 0.520 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2017 | 3 | 0.510 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2017 | 4 | 0.510 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 7 | 0.510 |
Why?
|
| Paroxetine | 4 | 2017 | 8 | 0.490 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 21 | 0.480 |
Why?
|
| Infant | 3 | 2023 | 78 | 0.470 |
Why?
|
| Risk | 11 | 2017 | 34 | 0.470 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 96 | 0.440 |
Why?
|
| Substance-Related Disorders | 3 | 2023 | 47 | 0.440 |
Why?
|
| Atrial Fibrillation | 2 | 2024 | 15 | 0.420 |
Why?
|
| Affect | 1 | 2014 | 29 | 0.400 |
Why?
|
| Middle Aged | 15 | 2023 | 967 | 0.400 |
Why?
|
| Case-Control Studies | 7 | 2023 | 81 | 0.400 |
Why?
|
| Antirheumatic Agents | 2 | 2023 | 7 | 0.400 |
Why?
|
| Cost-Benefit Analysis | 3 | 2024 | 18 | 0.400 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2023 | 12 | 0.390 |
Why?
|
| Analgesics | 2 | 2024 | 6 | 0.390 |
Why?
|
| Cholesterol | 2 | 2023 | 17 | 0.380 |
Why?
|
| Mortality | 1 | 2012 | 2 | 0.380 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2023 | 25 | 0.380 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 43 | 0.370 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 25 | 0.360 |
Why?
|
| Young Adult | 5 | 2024 | 787 | 0.340 |
Why?
|
| Linear Models | 2 | 2023 | 58 | 0.340 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 83 | 0.330 |
Why?
|
| Alzheimer Disease | 2 | 2022 | 62 | 0.320 |
Why?
|
| Primary Health Care | 2 | 2021 | 46 | 0.310 |
Why?
|
| Heart Failure | 3 | 2015 | 30 | 0.310 |
Why?
|
| Prescription Drugs | 3 | 2019 | 15 | 0.300 |
Why?
|
| Smoking Cessation | 3 | 2016 | 135 | 0.300 |
Why?
|
| Parkinson Disease | 2 | 2020 | 39 | 0.290 |
Why?
|
| Drug Therapy, Combination | 7 | 2023 | 26 | 0.280 |
Why?
|
| Health Personnel | 2 | 2019 | 20 | 0.280 |
Why?
|
| Infant, Newborn | 2 | 2019 | 48 | 0.280 |
Why?
|
| Treatment Outcome | 6 | 2023 | 177 | 0.280 |
Why?
|
| Cognition | 2 | 2023 | 140 | 0.280 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2022 | 20 | 0.260 |
Why?
|
| Prescription Drug Monitoring Programs | 2 | 2017 | 7 | 0.260 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2024 | 7 | 0.260 |
Why?
|
| Markov Chains | 2 | 2024 | 19 | 0.250 |
Why?
|
| Cognitive Dysfunction | 2 | 2019 | 55 | 0.250 |
Why?
|
| SEER Program | 2 | 2024 | 7 | 0.250 |
Why?
|
| Adult | 10 | 2023 | 1567 | 0.250 |
Why?
|
| Risk Assessment | 3 | 2016 | 44 | 0.240 |
Why?
|
| Bupropion | 2 | 2016 | 8 | 0.240 |
Why?
|
| Varenicline | 2 | 2016 | 8 | 0.240 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2016 | 5 | 0.240 |
Why?
|
| Propensity Score | 6 | 2017 | 11 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2016 | 39 | 0.220 |
Why?
|
| Incidence | 7 | 2019 | 30 | 0.220 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 6 | 0.220 |
Why?
|
| Drug Monitoring | 1 | 2024 | 10 | 0.220 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 9 | 0.220 |
Why?
|
| Factor Xa Inhibitors | 1 | 2024 | 5 | 0.210 |
Why?
|
| Rivaroxaban | 1 | 2024 | 6 | 0.210 |
Why?
|
| Pyridones | 1 | 2024 | 8 | 0.210 |
Why?
|
| Interviews as Topic | 1 | 2024 | 24 | 0.210 |
Why?
|
| Time Factors | 2 | 2017 | 163 | 0.210 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 17 | 0.210 |
Why?
|
| Fractures, Bone | 2 | 2016 | 7 | 0.210 |
Why?
|
| Anticoagulants | 1 | 2024 | 13 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 15 | 0.210 |
Why?
|
| Accidental Falls | 2 | 2016 | 9 | 0.210 |
Why?
|
| Pyrazoles | 1 | 2024 | 19 | 0.210 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2015 | 16 | 0.210 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2024 | 2 | 0.210 |
Why?
|
| Aripiprazole | 1 | 2024 | 3 | 0.210 |
Why?
|
| Logistic Models | 3 | 2019 | 64 | 0.210 |
Why?
|
| Stroke | 1 | 2024 | 48 | 0.200 |
Why?
|
| Pharmacies | 1 | 2023 | 3 | 0.200 |
Why?
|
| Pain | 1 | 2024 | 41 | 0.200 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2023 | 12 | 0.200 |
Why?
|
| Biological Products | 1 | 2023 | 9 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 3 | 2020 | 176 | 0.200 |
Why?
|
| Pharmaceutical Services | 1 | 2023 | 18 | 0.200 |
Why?
|
| Pharmacy | 1 | 2023 | 16 | 0.190 |
Why?
|
| Cross Infection | 2 | 2020 | 19 | 0.190 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 3 | 0.190 |
Why?
|
| Obesity, Abdominal | 1 | 2022 | 6 | 0.190 |
Why?
|
| Mexico | 1 | 2022 | 18 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2023 | 11 | 0.180 |
Why?
|
| Hyperlipidemias | 1 | 2022 | 9 | 0.180 |
Why?
|
| Benzodiazepines | 3 | 2017 | 11 | 0.180 |
Why?
|
| HIV Infections | 1 | 2023 | 104 | 0.170 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2021 | 9 | 0.170 |
Why?
|
| Aftercare | 1 | 2021 | 6 | 0.170 |
Why?
|
| Muscarinic Antagonists | 4 | 2021 | 18 | 0.170 |
Why?
|
| Comorbidity | 5 | 2020 | 47 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2020 | 12 | 0.160 |
Why?
|
| Hepatic Encephalopathy | 1 | 2020 | 2 | 0.160 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2020 | 1 | 0.160 |
Why?
|
| Baths | 1 | 2020 | 1 | 0.160 |
Why?
|
| Drug Utilization | 1 | 2020 | 5 | 0.160 |
Why?
|
| Patient Readmission | 1 | 2020 | 8 | 0.160 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 44 | 0.160 |
Why?
|
| Critical Care | 1 | 2020 | 12 | 0.160 |
Why?
|
| Palliative Care | 1 | 2019 | 4 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 7 | 0.150 |
Why?
|
| Drug Utilization Review | 1 | 2019 | 2 | 0.150 |
Why?
|
| Withholding Treatment | 1 | 2019 | 10 | 0.150 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 2 | 0.150 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2019 | 6 | 0.150 |
Why?
|
| Blood Culture | 1 | 2019 | 1 | 0.150 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 1 | 0.150 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 2 | 0.150 |
Why?
|
| Equipment Contamination | 1 | 2019 | 3 | 0.150 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 4 | 0.150 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 4 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2019 | 12 | 0.140 |
Why?
|
| Body Weight | 1 | 2019 | 58 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 7 | 0.130 |
Why?
|
| Prescription Drug Misuse | 1 | 2017 | 9 | 0.130 |
Why?
|
| Controlled Substances | 1 | 2017 | 4 | 0.130 |
Why?
|
| Neoplasms | 1 | 2019 | 90 | 0.130 |
Why?
|
| Schizophrenic Psychology | 1 | 2016 | 3 | 0.120 |
Why?
|
| Schizophrenia | 1 | 2016 | 8 | 0.120 |
Why?
|
| Hip Fractures | 1 | 2016 | 3 | 0.120 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 12 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 2 | 0.120 |
Why?
|
| Drug Combinations | 3 | 2020 | 25 | 0.120 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 3 | 0.120 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 17 | 0.120 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 14 | 0.120 |
Why?
|
| Febrile Neutropenia | 1 | 2015 | 2 | 0.120 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2015 | 4 | 0.120 |
Why?
|
| Dyslipidemias | 1 | 2015 | 4 | 0.120 |
Why?
|
| Depressive Disorder | 1 | 2015 | 12 | 0.110 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 49 | 0.110 |
Why?
|
| Smoking | 1 | 2015 | 89 | 0.110 |
Why?
|
| Data Collection | 1 | 2013 | 14 | 0.100 |
Why?
|
| Methotrexate | 2 | 2023 | 5 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2023 | 5 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 2 | 2023 | 17 | 0.100 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 137 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2024 | 33 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2012 | 8 | 0.090 |
Why?
|
| Housing | 1 | 2012 | 9 | 0.090 |
Why?
|
| Residence Characteristics | 1 | 2012 | 23 | 0.090 |
Why?
|
| Rivastigmine | 2 | 2022 | 6 | 0.090 |
Why?
|
| Galantamine | 2 | 2022 | 6 | 0.090 |
Why?
|
| Phenylcarbamates | 2 | 2022 | 5 | 0.090 |
Why?
|
| Indans | 2 | 2022 | 7 | 0.090 |
Why?
|
| Piperidines | 2 | 2022 | 15 | 0.090 |
Why?
|
| Survival Rate | 2 | 2023 | 14 | 0.080 |
Why?
|
| Brain | 1 | 2012 | 195 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 258 | 0.080 |
Why?
|
| Decision Support Techniques | 2 | 2020 | 7 | 0.080 |
Why?
|
| Age Factors | 2 | 2019 | 65 | 0.060 |
Why?
|
| Sex Factors | 2 | 2019 | 76 | 0.060 |
Why?
|
| Patient Acuity | 1 | 2023 | 4 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2023 | 3 | 0.050 |
Why?
|
| Medically Underserved Area | 1 | 2023 | 4 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2023 | 2 | 0.050 |
Why?
|
| Research | 1 | 2023 | 9 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2023 | 26 | 0.050 |
Why?
|
| Lipids | 1 | 2022 | 20 | 0.050 |
Why?
|
| Quetiapine Fumarate | 2 | 2012 | 2 | 0.050 |
Why?
|
| Dibenzothiazepines | 2 | 2012 | 2 | 0.050 |
Why?
|
| Risperidone | 2 | 2012 | 2 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 8 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 14 | 0.050 |
Why?
|
| Tolterodine Tartrate | 1 | 2021 | 2 | 0.040 |
Why?
|
| Acetylcholinesterase | 1 | 2021 | 4 | 0.040 |
Why?
|
| Injections | 1 | 2021 | 9 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 19 | 0.040 |
Why?
|
| Gastrointestinal Agents | 1 | 2020 | 2 | 0.040 |
Why?
|
| Lactulose | 1 | 2020 | 2 | 0.040 |
Why?
|
| Neomycin | 1 | 2020 | 2 | 0.040 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2020 | 3 | 0.040 |
Why?
|
| Chlorhexidine | 1 | 2020 | 1 | 0.040 |
Why?
|
| Soaps | 1 | 2020 | 1 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2020 | 9 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2020 | 17 | 0.040 |
Why?
|
| Recurrence | 1 | 2020 | 23 | 0.040 |
Why?
|
| Cancer Pain | 1 | 2019 | 3 | 0.040 |
Why?
|
| Pain Management | 1 | 2019 | 14 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2019 | 40 | 0.040 |
Why?
|
| Peptic Ulcer | 1 | 2019 | 2 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2019 | 1 | 0.040 |
Why?
|
| Cost Savings | 1 | 2019 | 2 | 0.040 |
Why?
|
| Deprescriptions | 1 | 2019 | 3 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2019 | 8 | 0.040 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 14 | 0.040 |
Why?
|
| Prevalence | 1 | 2017 | 66 | 0.030 |
Why?
|
| Smoking Prevention | 1 | 2016 | 8 | 0.030 |
Why?
|
| Self-Injurious Behavior | 1 | 2016 | 7 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 30 | 0.030 |
Why?
|
| Medicare Part D | 1 | 2015 | 7 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 3 | 0.030 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2015 | 3 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 8 | 0.030 |
Why?
|
| Taxoids | 1 | 2015 | 4 | 0.030 |
Why?
|
| Causality | 1 | 2015 | 1 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 17 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2015 | 62 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 318 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 4 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2012 | 5 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 2 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 111 | 0.020 |
Why?
|